2 results match your criteria: "Hematology department Hospital Universitario Son Espases Palma de Mallorca Spain.[Affiliation]"
Janus kinase inhibitor ruxolitinib in combination with nilotinib and prednisone in patients with myelofibrosis (RuNiC study): A phase Ib, multicenter study.
EJHaem
May 2023
Haematological Malignancies Clinical Research Unit Hospital Universitario 12 de Octubre, Universidad Complutense, CNIO, CIBERONC Madrid Spain.
Article Synopsis
- This study investigated the safety and tolerability of a treatment combining ruxolitinib, nilotinib, and prednisone in patients with myelofibrosis (MF) who were either naïve or resistant to ruxolitinib.
- A total of 15 patients participated, with the majority having prior ruxolitinib treatment; most experienced adverse events, particularly hyperglycemia, although no deaths occurred and the combination showed acceptable tolerability.
- At Cycle 7, 27% of patients had significant spleen size reductions, indicating the treatment demonstrated relevant clinical activity in MF cases.